Related Experiment Video
Updated: May 27, 2026
![Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [13C]-octanoic Acid Breath Test](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F50301.jpg&w=3840&q=50)
12:24
Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [13C]-octanoic Acid Breath Test
Published on: March 23, 2013
Diabetic gastroparesis: Therapeutic options
Uazman Alam1, Omar Asghar, Rayaz Ahmed Malik
1Department of Cardiovascular Sciences, University of Manchester, Core Technology Facility (3rd Floor), Grafton Street, Manchester, M13 9NT, UK.
Summary
Diabetic gastroparesis (DG) management involves prokinetic agents and mechanical therapies. This review updates on current and novel treatments for delayed gastric emptying in diabetic patients.
Area of Science:
- Gastroenterology
- Endocrinology
- Pharmacology
Background:
- Diabetic gastroparesis (DG) is a complication of diabetes mellitus, causing delayed gastric emptying and impacting quality of life.
- Symptoms like nausea and vomiting vary in severity and may not correlate with gastric emptying abnormalities.
- Current treatments include prokinetic agents and mechanical therapies, but novel approaches are emerging.
Purpose of the Study:
- To review current prokinetic and mechanical therapies for diabetic gastroparesis.
- To highlight novel investigational treatments for DG.
Main Methods:
- Literature review of prokinetic agents (metoclopramide, domperidone, erythromycin).
- Review of mechanical therapies (botulinum toxin injection, gastric electrical stimulation, gastrostomy/jejunostomy).
- Inclusion of novel agents targeting motilin receptors and ghrelin agonists.
Main Results:
- Prokinetic agents are standard but have side effects and interactions.
- Mechanical therapies are used for refractory cases.
- Investigational drugs like mitemcinal and TZP-101 show promise.
Conclusions:
- Existing therapies for DG have limitations.
- Novel pharmacological agents offer potential new treatment avenues for diabetic gastroparesis.
Related Concept Videos
01:15Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube through...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube through...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...